In vivo imaging using fluorescent antibodies to tumor necrosis factor predicts therapeutic response in Crohn's disease
Open accessAbstract
As antibodies to tumor necrosis factor (TNF) suppress immune responses in Crohn's disease by binding to membrane-bound TNF (mTNF), we created a fluorescent antibody for molecular mTNF imaging in this disease. Topical antibody administration in 25 patients with Crohn's disease led to detection of intestinal mTNF(+) immune cells during confocal laser endomicroscopy. Patients with high numbers of mTNF(+) cells showed significantly higher short-term response rates (92%) at week 12 upon subsequent anti-TNF therapy as compared to patients with low amounts of mTNF(+) cells (15%). This clinical response in the former patients was sustained over a follow-up period of 1 year and was associated with mucosal healing observed in follow-up endoscopy. These data indicate that molecular imaging with fluorescent antibodies has the potential to predict therapeutic responses to biological treatment and can be used for personalized medicine in Crohn's disease and autoimmune or inflammatory disorders.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Conventional endoscopic and histological assessment of disease activity alone have limitations in predicting therapeutic outcomes, highlighting the need to explore innovative approaches.
“Conventional endoscopic and histological assessment of disease activity alone have limitations in predicting therapeutic outcomes, highlighting the need to explore innovative approaches.79”
From Artificial intelligence and endo-histo-omics: new dimensions of precision endoscopy and histology in inflammatory bowel disease (2024) · cites this paper as [79]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 41 · Cited by 392
- Authors
- Atreya, R., Neumann, H., Neufert, C., Waldner, M. J., Billmeier, U., Zopf, Y., Willma, M., App, C., Münster, T., Kessler, H., Maas, S., Gebhardt, B., Heimke-Brinck, R., Reuter, E., Dörje, F., Rau, T. T., Uter, W., Wang, T. D., Kiesslich, R., Vieth, M., Hannappel, E., & Neurath, M. F.
- Affiliations
- Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
- University of Michigan (US)
- Bayreuth Medical Center (DE)
- Corresponding author
- Neurath, Markus F
- ORCID
- Venue
- Nature Medicine
- Published
- 2014-02-23
- Volume
- 20
- Issue
- 3
- Pages
- 313-318
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- PMC
- PMC4479137
- OpenAlex
- W2059452572
- Cited by
- 392
- References
- 41
- Citations by year
- 2026: 17 · 2025: 12 · 2024: 23 · 2023: 27 · 2022: 30 · 2021: 32 · 2020: 30 · 2019: 39 · 2018: 35 · 2017: 40 · 2016: 42 · 2015: 47 · 2014: 18
- FWCI
- 32.18
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Deutsche Forschungsgemeinschaft
- National Cancer Institute (U54CA163059, U54CA136429, R01CA142750, P50CA093990)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Inflammatory Bowel Disease
- Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Keywords
- Crohn's disease, TNF-α, membrane-bound TNF, fluorescent antibody, confocal laser endomicroscopy, adalimumab, anti-TNF therapy, treatment response prediction, intestinal mucosa, mucosal healing, personalized medicine, inflammatory bowel disease
- MeSH terms
- Adalimumab, Adult, Antibodies, Monoclonal, Crohn Disease, Female, Fluorescent Antibody Technique, Fluorescent Dyes, Humans, Immunoglobulin G, Immunotherapy, Inflammation, Intestinal Mucosa, Intestines, Male, Middle Aged, Prospective Studies, Tumor Necrosis Factor-alpha, Endoscopy, Gastrointestinal, Treatment Outcome, Microscopy, Confocal, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
